1. Pink Sheet
  2. >>Vaccines

How Africa Can Meet Its Daunting Production Challenge For Critical Disease Vaccines

 
• By Ian Schofield

Africa is taking steps to massively increase its vaccine production capacity and reduce its heavy dependence on other countries for supplies. Muthoni Wanyeki of the Open Society Foundations explained to the Pink Sheet how COVID-19 has highlighted the need for action and why it is important to keep up the momentum achieved so far.

Vaccination in Africa. Syringe with vaccine on flags of Africa countries on blue background.
Africa wants to reduce its dependence on vaccines from other countries • Source: Shutterstock

Here’s a question: Is it realistic to expect Africa to be able to manufacture 60% of the vaccines it uses in less than 20 years' time, compared with just 1% now? This is the objective that Africa has set itself for 2040.

“I think it’s feasible,” says Muthoni Wanyeki, regional director for Africa at the Open Society Foundations, a private philanthropic organization working in areas such as access to health and human rights

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

Legal, Process Problems May Plague New US FDA COVID-19 Vaccine Policy

 
• By Sarah Karlin-Smith

The FDA may have violated laws and regulations along with many norms in how it released its planned changes for COVID-19 vaccine approvals.

Observational, Retrospective Trials Could Retest Vaccines, HHS’ Kennedy Says

 
• By Derrick Gingery

The Health and Human Services secretary told a Senate appropriations subcommittee that placebo-controlled trials may not be necessary to ensure vaccine safety as the FDA released a framework requiring them for COVID-19 vaccines.

Novavax’s COVID-19 Vaccine Label Narrowed After Political Officials Intervened

 
• By Sarah Karlin-Smith

The label that Novavax's COVID-19 vaccine was slated to receive before political officials held up the approval was broader than was granted 16 May.

US FDA COVID-19 Booster Strategy May Not Be As Controversial As It Seems

 
• By Michael McCaughan

US FDA Commissioner Martin Makary’s call for placebo-controlled trials to confirm the efficacy of COVID-19 boosters is drawing a lot of criticism, but former Commissioner Robert Califf also supported the idea.

More from Pink Sheet

Spain Slashes Wait Between EU Drug Authorization And Financing Decisions

 
• By Francesca Bruce

Spanish authorities say that that timelines for drug reimbursement decisions can be improved further with the right submissions from companies.

Spain Beats England To Tevimbra Reimbursement Recommendations

 
• By Francesca Bruce

Spanish authorities have published more pricing and reimbursement reports as part of a new drive to increase transparency.

Commission Taking ‘Due Account’ Of Scathing Report On EU Clinical Trial Bottlenecks

 
• By Vibha Sharma

A report by the European pharmaceutical industry criticizes the EU’s clinical trials framework, highlighting regulatory fragmentation, inefficiencies and the need for targeted reforms.